This Solicitation opportunity from Department Of Defense was posted on July 29, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
DIBUCAINE OINTMENT
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
Dibucaine Ointment, USP, containing 1 percent dibucaine as the active ingredient, is supplied in a collapsible tube with a rectal applicator for external, rectal administration only. Each unit of issue is a package containing one ounce or 28 grams of the ointment, to be stored at temperatures between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit). The product is regulated by the FDA and must be marked in accordance with Medical Marking Standard No. 1, superseding MIL-STD-129, with preservation, packaging, and marking compliant with MIL-STD-2073-1E and supplemental instructions from MPWNN00001 Revision dated 03/30/1988. The item has a non-extendable shelf life of 36 months, classified as a TYPE I (CODE Q) item under RS020 and RS001 requirements. The National Stock Number is 6505-00-299-9535, with a manufacturer part number NDC00536-1211-95 provided by The Harvard Drug Group, L.L.C. The contract requires delivery of two packages, with a delivery window of 20 days from award, FOB destination at Nellis AFB, NV 89191, where inspection and acceptance will occur. No variance in quantity is permitted, and all shipments must meet commercial packaging standards suitable for carrier transport and export compliance. The solicitation number is SPE2DP-26-T-4358, issued by the Department of Defense’s Medical Supply Chain Pharm FSA, with proposals due by August 4, 2026, and submissions required exclusively through the DLA Internet Bid Board System. Compliance with FAR and DFARS clauses is mandatory, including equal opportunity for workers with disabilities, combating human trafficking, employment eligibility verification, sustainable products, hazardous material identification, and disclosure of information. The contract applies deviations for clauses related to trafficking, employment verification, sustainable products, hazardous materials, and cybersecurity requirements under NIST SP 800-171. Contractors must submit invoicing through Wide Area WorkFlow (WAWF), and representations regarding unique entity ID, CAGE code, small business status, and socioeconomic certifications are required. The contract includes provisions for whistleblower rights, compensation of former DoD officials,
General Info
Place of Performance
5601 STAFFORD DR BLDG 1301, NELLIS AFB, NV, 89191, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
DIBUCAINE OINTMENT<(>,<)> USP. CONTAINS 1 PERCENT OF DIBUCAINE OINTMENT
AS THE ACTIVE INGREDIENT. COMES SUPPLIED IN A COLLAPSIBLE TUBE AND
RECTAL APPLICATOR. RECTALLY ADMINISTERED. FOR EXTERNAL USE ONLY. UNIT OF
ISSUE IS A PACKAGE CONTAINING ONE (1) OUNCE OR 28 GRAMS. STORE AT 15-30
DEGREES CELSIUS OR 59 TO 86 DEGREES FARENHEIT.
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS
(IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE
DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB
AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description.
RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES
RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
Shall be marked IAW the latest edition of Medical Marking Standard No. 1 https://www.dla.mil/Logistics-Operations/Packaging/
THE HARVARD DRUG GROUP, L.L.C. 1LEZ0 P/N NDC00536-1211-95
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7017656190 0001 PG 2.000
NSN/MATERIAL:6505002999535
DELIVERY (IN DAYS):0020
SPE2DP-26-T-4358
SECTION B
PR: 7017656190 PRLI: 0001 CONT’D
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
SPECIAL NSN/Part Number: 6505-00-299-9535 Quantity: 2 PG Purchase Request: 7017656190QTY: 2 Delivery: 20 days ADO
More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
